A phase 1 study of MM-141, a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, in relapsed or refractory solid tumors

Authors
Category Primary study
JournalEuropean Journal of Cancer
Year 2016
This article has no abstract
Epistemonikos ID: 3579d5826a758a2b823fc828900dfbb9010b2d40
First added on: Feb 08, 2025